Consent given pursuant to sections 14 and 14A for the supply of the therapeutic goods specified by Johnson & Johnson Pacific Pty Limited

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth of Australia, was introduced to regulate the provision of therapeutic goods, ensuring their quality, safety, and efficacy. This Act empowers the Therapeutic Goods Administration, an entity within the Department of Health, to administer and enforce the provisions related to therapeutic goods. The policy objective of the Act is to protect public health by regulating the supply, advertising, and representation of therapeutic goods, thereby maintaining high standards for the safety and quality of these goods in the market. On 5 June 2015, a specific consent was granted under sections 14 and 14A of the Act for the supply of certain batches of Sudafed PE sinus and anti-inflammatory pain relief tablets that did not fully comply with the upcoming labelling requirements set to be enforced from 12 December 2015. This consent, provided by the delegate of the Secretary, allowed for a temporary exemption for particular batches, ensuring a smooth transition period for the manufacturer to align their products with the new regulatory standards.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation and control of therapeutic goods within Australia, which includes medicines, medical devices, and other related products. This legislation covers a broad range of entities such as manufacturers, importers, and suppliers of therapeutic goods, and it encompasses various aspects of their production, supply, advertising, and sponsorship. The Act has a nationwide reach, applying to the whole of Australia, and it is enforced by the Therapeutic Goods Administration, which is part of the Department of Health. The Act includes provisions for the classification, evaluation, and registration of therapeutic goods, and it sets standards for their quality, efficacy, and safety. Specific exclusions and exemptions from the Act are outlined within its various sections, and there are thresholds that determine the level of regulation applied to different types of therapeutic goods. The scope of the Act can be extended through subordinate instruments such as regulations and standards, which provide further detail on specific requirements and procedures.

Key Provisions

Under the Therapeutic Goods Act 1989, sections 14 and 14A provide the legal basis for the Therapeutic Goods Administration (TGA) to issue consent for the supply of therapeutic goods that do not fully comply with specified requirements. In this case, section 14 grants the Secretary of the Department of Health the authority to provide consent for the supply of therapeutic goods that do not conform to certain labelling requirements. This consent allows Johnson & Johnson Pacific Pty Limited to supply batches of SUDAFED PE SINUS & ANTI-INFLAMMATORY PAIN RELIEF tablets, specifically batches 5CV0511 and 5CV0531 (in 20-tablet packs) and batch 5CV0411 (in 48-tablet packs), with labels that do not meet the new warning requirements set out in the Therapeutic Goods Order No. 69, which will be mandated by the Medicines Advisory Statements Specification 2014. This consent is effective until 15 April 2016, providing a temporary exception to the upcoming labelling requirements. The Therapeutic Goods Act 1989 imposes certain obligations on entities supplying therapeutic goods. Specifically, entities must ensure that their products comply with the applicable legislative and regulatory requirements. For Johnson & Johnson Pacific Pty Limited, this includes adhering to the labelling standards specified in the Therapeutic Goods Orders. While this consent allows for a temporary deviation from the new warning label requirements, it is crucial that the company ensures all other aspects of the product meet the necessary standards. Additionally, the consent condition mandates that the labels used must be those provided by Johnson & Johnson Pacific Pty Limited on 4 June 2015, highlighting the need for precise compliance with the terms of the consent. Breaches of the Therapeutic Goods Act 1989 and its associated regulations can result in both civil and criminal penalties. Section 32 of the Act provides for the imposition of financial penalties for offences related to the supply of therapeutic goods that do not comply with legislative requirements. The maximum penalty for an individual is $220,000, while for a body corporate, the penalty can be significantly higher, reaching up to $1,100,000. Additionally, under section 33, supplying therapeutic goods that are not compliant can be considered a criminal offence, potentially leading to imprisonment for individuals and further financial penalties for corporate entities. It is therefore imperative for Johnson & Johnson Pacific Pty Limited to adhere strictly to the terms and conditions of the consent to avoid potential legal repercussions.